488 related articles for article (PubMed ID: 25881142)
1. Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.
Chiasserini D; Paciotti S; Eusebi P; Persichetti E; Tasegian A; Kurzawa-Akanbi M; Chinnery PF; Morris CM; Calabresi P; Parnetti L; Beccari T
Mol Neurodegener; 2015 Mar; 10():15. PubMed ID: 25881142
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies.
Moors TE; Paciotti S; Ingrassia A; Quadri M; Breedveld G; Tasegian A; Chiasserini D; Eusebi P; Duran-Pacheco G; Kremer T; Calabresi P; Bonifati V; Parnetti L; Beccari T; van de Berg WDJ
Mol Neurobiol; 2019 Feb; 56(2):1344-1355. PubMed ID: 29948939
[TBL] [Abstract][Full Text] [Related]
3. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
[TBL] [Abstract][Full Text] [Related]
4. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
[TBL] [Abstract][Full Text] [Related]
5. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease.
Huebecker M; Moloney EB; van der Spoel AC; Priestman DA; Isacson O; Hallett PJ; Platt FM
Mol Neurodegener; 2019 Nov; 14(1):40. PubMed ID: 31703585
[TBL] [Abstract][Full Text] [Related]
6. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
7. A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells.
Deen MC; Zhu Y; Gros C; Na N; Gilormini PA; Shen DL; Bhosale S; Anastasi N; Wang R; Shan X; Harde E; Jagasia R; Lynn FC; Vocadlo DJ
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2200553119. PubMed ID: 35858317
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase and Parkinson disease: Recent advances.
Schapira AH
Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
[TBL] [Abstract][Full Text] [Related]
9. [GBA mutations and Parkinson's disease].
Wang DX; Xie JX; Song N
Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
[TBL] [Abstract][Full Text] [Related]
10. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase dysfunction in neurodegenerative disease.
Brooker SM; Krainc D
Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
[TBL] [Abstract][Full Text] [Related]
12. Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export.
Martin S; Smolders S; Van den Haute C; Heeman B; van Veen S; Crosiers D; Beletchi I; Verstraeten A; Gossye H; Gelders G; Pals P; Hamouda NN; Engelborghs S; Martin JJ; Eggermont J; De Deyn PP; Cras P; Baekelandt V; Vangheluwe P; Van Broeckhoven C;
Acta Neuropathol; 2020 Jun; 139(6):1001-1024. PubMed ID: 32172343
[TBL] [Abstract][Full Text] [Related]
13. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity.
Ysselstein D; Young TJ; Nguyen M; Padmanabhan S; Hirst WD; Dzamko N; Krainc D
Mov Disord; 2021 Dec; 36(12):2719-2730. PubMed ID: 34613624
[TBL] [Abstract][Full Text] [Related]
15. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.
Blanz J; Saftig P
J Neurochem; 2016 Oct; 139 Suppl 1():198-215. PubMed ID: 26860955
[TBL] [Abstract][Full Text] [Related]
17. Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies.
Paciotti S; Gatticchi L; Beccari T; Parnetti L
Clin Chim Acta; 2019 Aug; 495():13-24. PubMed ID: 30922855
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
19. Measurement of GCase Activity in Cultured Cells.
Shojima Y; Ogata J; Tsunemi T; Imai Y; Hattori N
Methods Mol Biol; 2021; 2322():47-52. PubMed ID: 34043191
[TBL] [Abstract][Full Text] [Related]
20. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
